# Nita Patel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nita-patel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,051 |
| Field | SARS-CoV-2 and COVID-19 Research |
| h-index | 34 |
| i10-index | 65 |
| Last Known Institution | Novavax (United States) |
| OpenAlex ID | https://openalex.org/A5103002412 |
| ORCID iD | 0000-0003-4976-061X |
| Works | 105 |

## Researcher papers

- [Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine](https://scholariq.org/papers/phase-1-2-trial-of-a-sars-cov-2-recombinant-spike-protein-nanoparticle-vaccine/)
- [Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.](https://scholariq.org/papers/recommendations-for-the-identification-of-chronic-hepatitis-c-virus-infection/)
- [SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice](https://scholariq.org/papers/sars-cov-2-spike-glycoprotein-vaccine-candidate-nvx-cov2373-immunogenicity-in/)
- [Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate](https://scholariq.org/papers/structural-analysis-of-full-length-sars-cov-2-spike-protein-from-an-advanced/)
- [Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract](https://scholariq.org/papers/development-of-motavizumab-an-ultra-potent-antibody-for-the-prevention-of/)
- [Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences](https://scholariq.org/papers/increasing-the-affinity-of-a-human-igg1-for-the-neonatal-fc-receptor-biological/)
- [A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants](https://scholariq.org/papers/a-highly-potent-extended-half-life-antibody-as-a-potential-rsv-vaccine-surrogate/)
- [A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults](https://scholariq.org/papers/a-novel-investigational-fc-modified-humanized-monoclonal-antibody-motavizumab/)
- [The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings](https://scholariq.org/papers/the-cost-effectiveness-of-birth-cohort-screening-for-hepatitis-c-antibody-in-u-s/)
- [NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge](https://scholariq.org/papers/nvx-cov2373-vaccine-protects-cynomolgus-macaque-upper-and-lower-airways-against/)
- [Improving the Rate of Preschool Vision Screening: An Interrupted Time-Series Analysis](https://scholariq.org/papers/improving-the-rate-of-preschool-vision-screening-an-interrupted-time-series/)

## Researcher topics

- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Respiratory viral infections research](https://scholariq.org/topics/respiratory-viral-infections-research/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Viral gastroenteritis research and epidemiology](https://scholariq.org/topics/viral-gastroenteritis-research-and-epidemiology/)
- [Animal Virus Infections Studies](https://scholariq.org/topics/animal-virus-infections-studies/)

## Researcher university

- [Novavax (United States)](https://scholariq.org/institutions/novavax-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.